Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
Open Access
- 25 August 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 699949
- https://doi.org/10.3389/fphar.2021.699949
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative therapeutic efficacy and adverse effects of anti-COVID-19 drugs.Funding Information
- Xinxiang Medical University
This publication has 230 references indexed in Scilit:
- Arbidol as a broad-spectrum antiviral: An updateAntiviral Research, 2014
- Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)PLOS ONE, 2013
- Pharmacokinetic properties and bioequivalence of two formulations of arbidol: An open-label, single-dose, randomized-sequence, two-period crossover study in healthy chinese male volunteersClinical Therapeutics, 2009
- Adverse Events Associated with High‐Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Adverse side‐effects to biological agentsAllergy, 2006
- Lopinavir/RitonavirDrugs, 2006
- Side Effects of Interferon-α TherapyPharmacy World & Science, 2005
- Effects of chloroquine on viral infections: an old drug against today's diseasesThe Lancet Infectious Diseases, 2003
- Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?Atherosclerosis, 2003
- Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfectionThe Lancet, 2001